Galleon Pharmaceuticals Inc., of Horsham, Pa., reported clinically and statistically significant (p < 0.01) results from a double-blind, placebo-controlled clinical proof-of-concept study of its lead investigational compound, GAL-021, in normal volunteers. Data were published in the most recent issue of Anesthesiology.